Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Alice Tsang Shaw, MD, PhD, and Tony Mok, MD: Results From the ARCHER 1050 Trial

Posted: Thursday, June 15, 2017

Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss phase III study findings on dacomitinib vs gefitinib for first-line treatment of advanced EGFR mutation–positive non–small cell lung cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.